Isavuconazole treatment of a patient with disseminated mucormycosis

Journal of Clinical Microbiology

Volumn 52, Issue 3, 2014, Pages 1016-1019

  Peixoto, Driele ^a   Gagne, Lisa S ^a   Hammond, Sarah P ^a,b,c   Gilmore, Erin T ^a   Joyce, Amy C ^b   Soiffer, Robert J ^b,c   Marty, Francisco M ^a,b,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; ASPARTATE AMINOTRANSFERASE; AZACITIDINE; CEFTAZIDIME; CYTARABINE; DAUNORUBICIN; HYDROXYUREA; ISAVUCONAZOLE; MICAFUNGIN; POSACONAZOLE; SORAFENIB; VANCOMYCIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHASIA; ARTICLE; BACTERIAL PNEUMONIA; BONE MARROW BIOPSY; BRAIN EDEMA; CASE REPORT; CATHETER INFECTION; CATHETER REMOVAL; COMPUTER ASSISTED TOMOGRAPHY; CRACKLE; DETERIORATION; DISSEMINATED MUCORMYCOSIS; DNA SEQUENCE; DONOR LYMPHOCYTE INFUSION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECG ABNORMALITY; FEVER; FOLLOW UP; HUMAN; HUMAN TISSUE; KIDNEY TUBULE DISORDER; LEUKEMIA RELAPSE; LOADING DRUG DOSE; LUNG INFILTRATE; MALE; MIDDLE AGED; MUCORMYCOSIS; MUCOSA INFLAMMATION; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; RENAL TUBULAR MAGNESIUM WASTING; RENAL TUBULAR POTASSIUM WASTING; RHIZOMUCOR MIEHEI; RHIZOMUCOR PUSILLUS; SEIZURE; SHOULDER PAIN; SKIN BIOPSY;

ANTIFUNGAL AGENTS; BRAIN; HUMANS; IMMUNOCOMPROMISED HOST; LEUKEMIA, MYELOID, ACUTE; LUNG; MALE; MIDDLE AGED; MUCORMYCOSIS; NITRILES; PYRIDINES; RHIZOMUCOR; SKIN; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; TRIAZOLES;

EID: 84894541569     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.03176-13     Document Type: Article

References (14)

1. Hammond SP, Bialek R, Milner DA, Petschnigg EM, Baden LR, Marty FM. 2011. Molecular methods to improve diagnosis and identification of mucormycosis. J. Clin. Microbiol. 49:2151-2153. http://dx.doi.org/10.1128/JCM.00256-11.
2. Bialek R, Konrad F, Kern J, Aepinus C, Cecenas L, Gonzalez GM, Just-Nubling G, Willinger B, Presterl E, Lass-Florl C, Rickerts V. 2005. PCR based identification and discrimination of agents of mucormycosis and aspergillosis in paraffin wax embedded tissue. J. Clin. Pathol. 58: 1180-1184. http://dx.doi.org/10.1136/jcp.2004.024703. (Pubitemid 41566463)
3. Spellberg B, Edwards J, Jr, Ibrahim A. 2005. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin. Microbiol. Rev. 18:556-569. http://dx.doi.org/10.1128/CMR.18.3.556-569.2005. (Pubitemid 40995116)
4. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653. http://dx.doi.org/10.1086/432579. (Pubitemid 41170352)
5. Hammond SP, Baden LR, Marty FM. 2011. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob. Agents Chemother. 55:5018-5021. http://dx.doi.org/10.1128/AAC. 00536-11.
6. Ervens J, Ghannoum M, Graf B, Schwartz S. 12 November 2013. Successful isavuconazole salvage therapy in a patient with invasive mucormycosis. Infection http://dx.doi.org/10.1007/s15010-013-0552-6.
7. Andes D, Pascual A, Marchetti O. 2009. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrob. Agents Chemother. 53:24-34. http://dx.doi.org/10.1128/AAC.00705-08.
8. Rüping MJ, Albermann N, Ebinger F, Burckhardt I, Beisel C, Müller C, Vehreschild JJ, Kochanek M, Fätkenheuer G, Bangard C, Ullmann AJ, Herr W, Kolbe K, Hallek M, Cornely OA. 2008. Posaconazole concentrations in the central nervous system. J. Antimicrob. Chemother. 62: 1468-1470. http://dx.doi.org/10.1093/jac/dkn409.
9. Reinwald M, Uharek L, Lampe D, Grobosch T, Thiel E, Schwartz S. 2009. Limited penetration of posaconazole into cerebrospinal fluid in an allogeneic stem cell recipient with invasive pulmonary aspergillosis. Bone Marrow Transplant. 44:269-270. http://dx.doi.org/10.1038/bmt.2009.17.
10. Pasqualotto AC, Denning DW. 2008. New and emerging treatments for fungal infections. J. Antimicrob. Chemother. 61(Suppl 1):i19 -i30. http://dx.doi.org/ 10.1093/jac/dkm428.
11. Pasqualotto AC, Thiele KO, Goldani LZ. 2010. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr. Opin. Investig. Drugs 11:165-174.
12. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1, 007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52: 1396-1400. http://dx.doi.org/10.1128/AAC.01512-07. (Pubitemid 351522004)
13. Livermore J, Hope W. 2012. Evaluation of the pharmacokinetics and clinical utility of isavuconazole for treatment of invasive fungal infections. Expert Opin. Drug Metab. Toxicol. 8:759-765. http://dx.doi.org/10.1517/17425255. 2012.683859.
14. Gagne LS, Hammond SP, Gilmore ET, Joyce AC, Soiffer RJ, Marty FM. 2011. Abstr. 49th Annu. Meet. Infect. Dis. Soc. Am., Boston, MA, 22 October 2011, abstr 901.